Article
Higher cell stiffness indicating lower metastatic potential in B16 melanoma cell variants and in (-)-epigallocatechin gallate-treated cells.
Research Institute for Clinical Oncology, Saitama Cancer Center, Kitaadachi-gun, Saitama, 362-0806, Japan, .
Journal of Cancer Research and Clinical Oncology (impact factor:
2.56).
02/2012;
DOI:10.1007/s00432-012-1159-5
Source: PubMed
-
Citations (0)
-
Cited In (0)
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
2 times higher
AFM measurements
atomic force microscopy
cell migration
cell stiffness
cell stiffness 2-fold
inhibited migration
key nanomechanical feature
likely metastatic potential
low motile
measure stiffness
metastatic B16 melanoma variants
metastatic B16-F1 cells
metastatic potential
migration potential
morphologically similar cells
motile B16-F10 cells
Nanomechanical stiffness
reliable quantitative indicator
Transwell assay